Scientist working with human cell culture plates in a laminar flow hood alongside fluorescent microscopy imagery

New Approach Methodologies

NAMs, applied with a defined context of use.

Organ-on-chip systems, human organoids, precision-cut human lung slices, air–liquid interface airway cultures coupled to aerosol exposure, high-throughput screens, and in silico models are a genuine addition to the toolbox. Their value depends entirely on whether the question you are asking is one they can answer — so we define that question first, every time.

Organ-on-chip systems Human organoids & precision-cut tissue Air–liquid interface airway cultures High-throughput screening In silico modeling Context of use — first, always

New Approach Methodologies is one service within Preclinical Development Services — alongside pharmacology, general toxicology, inhalation toxicology, DMPK, formulation, and bioanalytical chemistry.

Talk to Our Team

Our Operating Principle

The question decides the model. Not the other way around.

A NAM is a genuine scientific instrument — used badly, it is also the fastest way to get an unreliable answer to the wrong question.

Define the context of use — what question is being addressed — to maximize clinical and translational impact. Our operating principle for every NAM we run.

NAMs are highly fit-for-purpose tools, not generalized substitutes. A precision-cut human lung slice can preserve diseased architecture and give a more predictive efficacy read in pulmonary fibrosis, where animal models are prone to false positives. That same slice cannot speak to pharmacokinetics, off-target effects, or systemic toxicity.

So we start where the question starts. Where a NAM is the better instrument — early screening, mechanism, target-specific modeling — we use it, and it reduces animal use. Where the question is systemic — how a compound circulates, accumulates, is metabolized, engages the immune system, or produces delayed toxicity — validated animal models remain the most reliable framework, and most IND-enabling programs still rely on them for regulatory submissions.

That judgment is the service. Not access to a platform.

Scientist working with human cell culture plates in a laminar flow hood alongside fluorescent microscopy imagery Human cell & tissue model systems

Where we reach for a NAM

Narrow, specific, mechanistically framed questions.

  • Early screening and triage across candidate series
  • Mechanism of action in human cells and tissue
  • Target-specific modeling and pathway interrogation
  • Indications where the animal model is known to be non-predictive
  • Reducing and refining animal use ahead of an in vivo study

Where validated animal models still carry the program

Whole-body questions a single-organ system cannot reach.

  • Pharmacokinetics, biodistribution, and tissue accumulation
  • Off-target and multi-organ effects
  • Immune-system interactions and metabolism
  • Chronic exposure and delayed toxicity
  • IND-enabling packages supporting regulatory submissions

Regulatory clarity is still uneven. FDA has signalled that in vitro models may suffice for certain monoclonal antibody safety assessments where animal models are non-predictive, but comparable allowances have not been extended to small molecules or other biologics — so a NAM belongs in a package with scientific justification behind it, not in place of one. Our view on integrating the two is set out in Bridging Innovation and Reliability: Why Animal Studies Still Matter in the Age of NAMs, by Edward G. Barrett, PhD, in Pharmaceutical Executive.

How We Decide

A consistent framework, applied to every program.

The same four steps run whether the eventual design is fully in vivo, fully in vitro, or a hybrid of both.

01

Define the context of use

Name the specific question the data has to answer and the decision it will inform.

02

Match the modality

Test that question against what a NAM can and cannot answer, and against what an animal model can and cannot answer.

03

Design for the gap

Where a NAM covers the mechanism but not the systemic picture, pair it with the in vivo work that closes that gap.

04

Report with judgment

Deliver an interpretation built for your next regulatory or partnering conversation — not just a dataset.

Systems in Practice

Human airway epithelium at the air–liquid interface, dosed by aerosol.

Primary human airway epithelial cells — bronchial or nasal, from healthy or diseased donors — differentiate into a ciliated, mucus-producing barrier that behaves like the conducting airway. Coupled to our aerosol exposure systems, candidates deposit on the epithelial surface as a respirable cloud: the route a patient’s lung actually sees.

Cells are seeded on porous supports and lifted to air–liquid interface culture, where they mature into a pseudostratified epithelium — ciliated cells with active mucociliary clearance, mucus-secreting goblet cells, and tight junctions that give a measurable barrier. Because the cultures come from individual donors, healthy and diseased populations — asthma, COPD, cystic fibrosis, idiopathic pulmonary fibrosis — run side by side in the same experiment.

What makes the platform translational is the exposure. Nebulized solutions, dry powder inhalers, and spray formulations are aerosolized and delivered through exposure chambers that control particle size, concentration, humidity, and duration — so the deposited dose is quantifiable per unit surface area. Efficacy and toxicity readouts anchor to a real delivered dose, and candidates rank before an animal is dosed.

What we measure

  • Barrier integrity — TEER and paracellular permeability
  • Ciliary beat frequency and mucociliary transport
  • Mucus secretion — MUC5AC and MUC5B
  • Cytokine and mediator release into the basolateral compartment
  • Viral and bacterial burden on infected cultures
  • Cytotoxicity — LDH, ATP viability, and histology
Aerosol Generationnebulizer · dry powder · sprayExposure Chamberaerosol cloud deposits on the apical surfacecultures held at the air–liquid interfaceExposure ControlsDeposition dose — µg/cm²Particle size — MMAD and GSDHumidity and temperatureFlow rate and exposure durationMultiple donors in parallelSingle Culture Insert — Cross-SectionQuantified deposition doseµg per cm² of epitheliumMucus and periciliary layerDifferentiated epithelium —ciliated, goblet, and basal cellsPorous membrane insertBasolateral media —sampled for secreted mediators
Schematic — human airway epithelial culture at the air–liquid interface, integrated with an aerosol exposure system. The test article is generated as a respirable aerosol (nebulized solution, dry powder, or spray), conditioned in the exposure chamber, and deposited onto the apical surface of differentiated epithelium grown on a porous insert. Tissue readouts report barrier, ciliary, and viability endpoints; the basolateral media is sampled for secreted mediators.
01

Small Molecules

Inhaled anti-inflammatories · bronchodilators · antifibrotics

Efficacy and injury read against quantified deposition — cytokine suppression, barrier integrity, and viability per unit dose. Dose–response curves rank candidate series and formulations before any animal study is dosed.

02

Biologics

Inhaled antibodies · peptides · enzymes

Aerosol stability and delivered activity after nebulization; mucosal binding and receptor engagement at the epithelial surface; barrier tolerance of excipients and repeated dosing.

03

Gene Therapy and RNA

AAV and lentiviral vectors · mRNA and siRNA nanoparticles · antisense oligonucleotides

Transduction and transfection efficiency after aerosol delivery across bronchial and nasal epithelium, functional correction endpoints such as CFTR, and barrier integrity under repeat exposure.

04

Infectious Disease

RSV · influenza A · SARS-CoV-2 · rhinovirus · Pseudomonas

Viruses and bacteria replicate in differentiated epithelium at the mucosal surface. Antiviral and antibacterial efficacy is measured against replicating pathogen, with pre- and post-exposure prophylaxis and therapeutic windows.

05

Vaccines and Mucosal Immunity

Intranasal and inhaled vaccine candidates

Antigen delivery across the epithelial barrier, mucosal immune signalling, and donor-matched durability of response — a screen for vaccine formats before moving into animals.

06

Safety and Tolerability

Excipients · impurities · device materials · environmental aerosols

Dose-dependent injury, mucus hypersecretion, ciliary dysfunction, and irritancy — screening that de-risks candidates and formulations before in vivo inhalation studies.

The platform slots in at Stage 02 of our decision framework: where the question is how a candidate behaves at the human airway surface — before, during, or after aerosol delivery — ALI cultures generate the answer, and the results rank candidates and formulations ahead of in vivo work. Where the question turns systemic, the same program transitions into validated inhalation models. Discuss an ALI aerosol study.

In Practice

Human cells first, then the clinic: human milk oligosaccharides.

A worked example of context of use — a human in vitro system answered the mechanistic question, and that answer shaped a clinical program that reached the market.

Lovelace scientists contributed to both the in vitro mechanism work and the immune endpoints of the clinical trial that followed.

Stage 01 · Context of use

Frame a question a human cell model can answer

Could individual human milk oligosaccharides directly reduce respiratory viral infection and the inflammatory signalling tied to disease severity? That is a mechanistic question about human airway biology — not a systemic exposure question. So it was posed in human cells.

Stage 02 · Human in vitro NAM

Answer it in human airway epithelium and PBMCs

In human airway epithelial cells and peripheral blood mononuclear cells, 2'-FL significantly reduced RSV viral load and the cytokines associated with severity and inflammation — IL-6, IL-8, MIP-1α, TNF-α, and MCP-1 — at concentrations at or below those found in breast milk. LNnT and 6'-SL reduced influenza A viral load.

Duska-McEwen G, Senft AP, Ruetschilling TL, Barrett EG, Buck RH. Human milk oligosaccharides enhance innate immunity to respiratory syncytial virus and influenza in vitro. Food Nutr Sci. 2014;5:1387–1398. scirp.org
Stage 03 · Into the clinic

Carry the same endpoint into a randomized trial

The in vitro cytokine signal defined what to measure in humans. In a randomized controlled trial, infants fed formula containing 2'-FL had 29–83% lower plasma inflammatory cytokines than controls — IL-1ra, IL-1α, IL-1β, IL-6, and TNF-α — indistinguishable from a breastfed reference group, with the same pattern reproduced in ex vivo RSV-stimulated PBMC cultures.

Goehring KC, Marriage BJ, Oliver JS, Wilder JA, Barrett EG, Buck RH. J Nutr. 2016;146(12):2559–2566. PubMed
Stage 04 · Market

Regulatory clearance and a marketed product

The mechanistic and clinical evidence base supported 2'-FL through FDA GRAS notification — reviewed with no questions from the agency — and into commercial infant formula, where it is now permitted at up to 2.4 g/L.

FDA GRAS Notice inventory, 2'-fucosyllactose. FDA

Why this is the model for how we use NAMs

In this case, the human in vitro system was the instrument that made the clinical program answerable. It identified the active molecule, the mechanism, and the specific cytokine endpoints worth measuring in infants, which is exactly what a fit-for-purpose NAM is for.

Define the context of use, choose the system that fits it, and each result earns the next stage. That is how a mechanistic finding becomes a marketed product.

Not sure if your question needs a NAM, an animal model, or both?

Send us your target, mechanism, and the decision the next study has to inform. We will tell you which system actually answers it — and why.